Name: REGENERON PHARMACEUTICALS (REGN) Stock
Brand: REGENERON PHARMACEUTICALS
Rating: 6.5 (3 reviews)

REGN Latest News, Press Relases and Analysis

All

Press Releases

6 days ago - By: Chartmill - Mentions: SHW NUE BRO ARE ...

Uncover the latest developments among S&P500 stocks in today's session.

6 days ago - By: Chartmill - Mentions: SHW NUE BRO ARE ...

Explore the top gainers and losers within the S&P500 index in today's session.

3 days ago - By: Regeneron Pharmaceuticals, Inc.

Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award

3 days ago - By: Regeneron Pharmaceuticals, Inc.

Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award

6 days ago - By: The Motley Fool

Regeneron (REGN) Q3 2025 Earnings Call Transcript

6 days ago - By: Benzinga - Mentions: THC XLRE ZBRA UHS ...

Nasdaq 100 Hits 26,000, Gold Falls Below $4,000: What's Moving Markets Tuesday?

6 days ago - By: Chartmill - Mentions: SHW ARE UPS RCL ...

These S&P500 stocks are gapping in today's session

6 days ago - By: Chartmill - Mentions: SHW IVZ ARE UNH ...

These S&P500 stocks that are showing activity before the opening bell on Tuesday.

6 days ago - By: Investor's Business Daily

Regeneron's Earnings Took A Big Tax Hit, And Still Pounded Forecasts

6 days ago - By: Chartmill

Regeneron Pharmaceuticals (NASDAQ:REGN) Q3 2025 Earnings Beat Estimates

6 days ago - By: Regeneron Pharmaceuticals, Inc.

Regeneron Reports Third Quarter 2025 Financial and Operating Results

6 days ago - By: Regeneron Pharmaceuticals, Inc.

Regeneron Reports Third Quarter 2025 Financial and Operating Results

7 days ago - By: Benzinga

A Preview Of Regeneron Pharmaceuticals's Earnings

11 days ago - By: Zacks Investment Research

Exploring Analyst Estimates for Regeneron (REGN) Q3 Earnings, Beyond Revenue and EPS

11 days ago - By: Zacks Investment Research - Mentions: ALNY ETNB

RHHBY's Sales Up 7% in First 9 Months of 2025, '25 Earnings View Raised

14 days ago - By: Zacks Investment Research - Mentions: BEAM NTLA CRSP

Can NTLA's In Vivo Pipeline Aid Long-Term Growth Amid Competition?

17 days ago - By: Investor's Business Daily - Mentions: RY RY.CA IRON RVMD ...

The FDA Just Granted Its Speediest Review Ever. Disc Medicine, Others Fly.

17 days ago - By: Regeneron Pharmaceuticals, Inc.

Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation

17 days ago - By: Regeneron Pharmaceuticals, Inc.

Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation

17 days ago - By: Stocktwits - Mentions: RVMD IRON SNY LLY ...

Revolution Medicines, Disc Medicine, Regeneron Stocks Jump After-Hours As FDA Fast-Tracks 9 Drugs Under New Review Program

18 days ago - By: Chartmill

Regeneron Pharmaceuticals (NASDAQ:REGN) Presents a Compelling Case for Value Investors

19 days ago - By: Regeneron Pharmaceuticals, Inc.

Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers

19 days ago - By: Regeneron Pharmaceuticals, Inc.

Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers

20 days ago - By: The Motley Fool - Mentions: DXCM

2 Stocks Down 17% and 21% to Buy Right Now

21 days ago - By: Chartmill - Mentions: MNST PM HSY CAG ...

REGENERON PHARMACEUTICALS (REGN) Stock News

REGN Latest News, Press Relases and Analysis

Uncover the latest developments among S&P500 stocks in today's session.

Explore the top gainers and losers within the S&P500 index in today's session.

Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award

Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award

Regeneron (REGN) Q3 2025 Earnings Call Transcript

Nasdaq 100 Hits 26,000, Gold Falls Below $4,000: What's Moving Markets Tuesday?

These S&P500 stocks are gapping in today's session

These S&P500 stocks that are showing activity before the opening bell on Tuesday.

Regeneron's Earnings Took A Big Tax Hit, And Still Pounded Forecasts

Regeneron Pharmaceuticals (NASDAQ:REGN) Q3 2025 Earnings Beat Estimates

Regeneron Reports Third Quarter 2025 Financial and Operating Results

Regeneron Reports Third Quarter 2025 Financial and Operating Results

A Preview Of Regeneron Pharmaceuticals's Earnings

Exploring Analyst Estimates for Regeneron (REGN) Q3 Earnings, Beyond Revenue and EPS

RHHBY's Sales Up 7% in First 9 Months of 2025, '25 Earnings View Raised

Can NTLA's In Vivo Pipeline Aid Long-Term Growth Amid Competition?

The FDA Just Granted Its Speediest Review Ever. Disc Medicine, Others Fly.

Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation

Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation

Revolution Medicines, Disc Medicine, Regeneron Stocks Jump After-Hours As FDA Fast-Tracks 9 Drugs Under New Review Program

Regeneron Pharmaceuticals (NASDAQ:REGN) Presents a Compelling Case for Value Investors

Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers

Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers

2 Stocks Down 17% and 21% to Buy Right Now

Gapping S&P500 stocks in Monday's session